"name","id","description","uuid:ID","text","instanceType","label"
"OBJ1","Objective_1","Main objective","360a6c6d-6fd9-4521-8a0b-4b1f54df9b1a","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective",""
"OBJ2","Objective_2","Safety","7594be50-891c-4c27-838f-e2e2ed85cc91","To document the safety profile of the xanomeline TTS.","Objective",""
"OBJ3","Objective_3","Behaviour","e629b74b-38b2-4306-8fcb-30513760842a","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective",""
